532

al080059 contig 63649rc loc51203 contig 46218rc contig 38288rc aa555029rc contig 28552rc flt1 mmp9 dc13 ext1 al137718 pk428 hec ect2 gmps contig 32185rc uch37 contig 35251rc kiaa1067 gnaz serf1a oxct orc6l l2dtl prc1 af052162 col4a2 kiaa0175 rab6b contig 55725rc dck cenpa sm20 mcm6 akap2 contig 56457rc rfc4 dkfzp564d0462 slc2a3 mp1 contig 40831rc contig 24252rc flj11190 contig 51464rc igfbp5 igfbp5 ccne2 esm1 contig 20217rc nmu loc57110 contig 63102rc peci ap2b1 cffm4 peci tgfb3 contig 46223rc contig 55377rc hsa250839 gstm3 bbc3 cegp1 contig 48328rc wisp1 aldh4 kiaa1442 contig 32125rc fgf18

­1

0

1

prognostic classi®er
contig 37571rc kiaa0882 ca12 esr1 gata3 myb p28 flj20262 al133619 contig 56390rc celsr1 contig 58301rc ugcg al049265 bcl2 emap-2 hsu79303 contig 51994rc contig 237rc contig 47045rc xbp1 hnf3a vav3 contig 54295rc al133074 contig 53968rc contig 49342rc zfp103 al110139 flj12538 erbb3 fbp1 contig 50297rc flj20273 al080192 tceb1l d5s346 al137761 tegt contig 41887rc

clustering
contig 27915rc contig 14390rc pou2af1 pim2 loc51237 loc57823 loc57823 aj249377 x93006 u96394 x79782 af063725 igll1 igl@ igl@ aj225092 igkv3d-15 af103458 aj225093 contig 10268rc contig 44195rc af058075 igl@ igkc tlx3 contig 42547 contig 20907rc icap-1a flj20340 af103530 mtr1 cd19 cd19 ighm vpreb3 bm040 kiaa0167 trd@ irf5 contig 50634rc

figure 1 unsupervised two-dimensional cluster analysis
autoimmune disease

121 dkklelkldikaakvtpaqtahgdsttasprtltterng-setqtlvtlhnnngtkistw mtim-3 120 dekfnlklvikpakvtpaptlqrdftaafprmlttrghgpaetqtlgslpdinltqistl htim-3

transmembrane region
180 adeikds---------getirtaihigvgvsagltlaliigvlilkwysckkkklsslsl mtim-3 180 anelrdsrlandlrdsgatirigiyigagicaglalalifgalifkwyshskekiqnlsl htim-3

cytoplasmic region
231 itlanlppgglanagavrirseeniytieenvyevensneyycyvns-qqps
signal peptide
1 mfsgltlncvllllqlllarsledgykvevgknaylpcsytlptsgtlvpmcwgkgfcpw mtim-3 1 mfshlpfdcvlllllllltrsseveyraevgqnaylpcfytpaapgnlvpvcwgkgacpv htim-3

igv domain
61 sqctnellrtdernvtyqkssryqlkgdlnkgdvsliiknvtlddhgtyccriqfpglmn mtim-3 61 fecgnvvlrtderdvnywts-rywlngdfrkgdvsltienvtladsgiyccriqipgimn htim-3

mucin domain
contig ests ending
named contig est
average good prognosis profile

sporadic breast tumours patients <55 years tumour size <5 cm lymph node negative
est contig
adjuvant systemic therapy
patient group consensus st gallen nih prognosis pro®le* total patient group
vegf receptor flt1
metalloproteinases mmp9
pk428
mcm6
rab6b
mp1
esm1
11

w3d8

w4f3

do11 tc2

tim-3

competing interests statement
mtim-3 240 islanlppsglanavaegirseeniytieenvyeveepneyycyvssrqqpsqplgcrfa htim-3 282 mtim-3 300 mp
high throughput gene expression pro®ling facility
good prognosis

figure 3 supervised classi®cation
metastases group received adjuvant systemic therapy consisting
unsupervised two-dimensional clustering
two-dimensional cluster analysis
cell surface protein tim-3 regulates macrophage activation
unsupervised cluster analysis distinguishes
gene expression pro®ling predicts clinical outcome
lymph node-negative breast cancer patients identi®ed
tumours

15 10 5 ­1 0 1

figure 2 supervised classi®cation
erbb3
bcl2
ae 10g tim mo 64 sc 02
powerful three-step supervised classi®cation method
world health organisation classi®cation
rat adrenal zona glomerulosa cells
average good prognosis pro®le
including axillary lymph node dissection
health consensus development conference statement
brca1 mediates ligand-independent transcriptional repression
prognostic pro®le potentially
11

7a5

4e8

do11 tc1

acknowledgements
th2 cells inhibits autoimmune diseases7
authors declare competing ®nancial interests
cells ells na na cd
neuro®bromin-de®cient mast cells
global gene expression pro®les
usa § va health care system
breast carcinomas distinguish tumor subclasses
vitro differentiated th1 cell lines derived
unsupervised clustering detects
naive cd4+ t-helper cells results
two-layer cluster analysis
hierarchical clustering algorithm allowed
agglomerative hierarchical clustering algorithm
breast cancer prognostic factors
esr1
remarkably distinct gene expression patterns
er supervised classi®cation
er signature gene set overlaps
prognosis classi®er selects
prognosis reporter genes distant metastases <5 years
unsupervised analysis
gene expression signature strongly predictive
two-level classi®cation system
st gallen consensus
previous studies measured protein levels
figure 3c shows
supervised two-layer classi®cation
two-dimensional display
tailor adjuvant systemic treatment
70 optimal prognostic marker genes
classi®er predicted correctly
unsupervised clustering
multiple mapk pathways revealed
ras-dependent chloride current activated
arti®cial neural networks
nf1-regulated adenylyl cyclase pathway
21st century divining rod
¯uorescent dye reversal technique
figure 3b shows
gene expression pro®le
poor prognosis pro®le
table 1 breast cancer patients eligible
breast cancer gene expression reported
lymph-node-negative young breast cancer patients
d2 ls 1ive ive
gene expression pro®ling
rat igg isotype control
de®nes er status
underlying biological mechanism leading
oligonucleotide probe design programme13
gene expression pro®les
average pro®le
competing interests statement
classical prognostic factors
paraf®n-embedded tumour tissue
similar classi®cation method8
er messenger rna measured
applied supervised classi®cation
modi®ed radical mastectomy
randomized adjuvant chemotherapy trial
histopathological prognostic factors
examples include cyclin d1
er classi®er
adjuvant systemic therapy
primary invasive breast carcinoma
plasminogen activator inhibitor type 1
human mammary epithelial cells
early breast cancer trialists
lymph node negative
karin van der kooy*
8 good prognosis patients assigned
prognostic reporter genes
231 prognostic reporter genes
figure 1 cloning
linking gene expression patterns
distinctive gene expression patterns
medical record data extraction
dominant gene cluster
th2 cells produce cytokines
classify accurately breast tumours
lymph node status
competing ®nancial interests
th1 cells produce cytokines
poor prognostic tumours
lymph node metastases
er status reporter signature
usa
cho mtim-3
70 prognostic marker genes
supplementary information table s2
supplementary information table s3
supplementary information table s4
prognosis classi®er
`prognosis classi®er
brca1 status reporter genes26
lymph-node-negative breast cancer patients
50 er status reporter genes
supervised classi®cation
methods
breast tumour selection criteria
550 optimal er reporter genes
qiagen rnase-free dnase kit
variable region
poor prognosis patients assigned
dna microarray analysis
expression pro®le
cross-validated classi®er
70-gene classi®er
classi®er presented
classi®er showed
opposite gene expression group
poor prognosis signature consists
reverse colour cy-labelled product
transmembrane protein
odds ratio de®nition
previous study de®ned
19 additional breast cancer patients
expression pro®ling
adjuvant systemic treatment
genes regulating cell cycle
supplementary information table s1
average size
national neuro®bromatosis foundation
st gallen
brca1 germline mutation carrier
breast tumours
tumour material
microarray classi®er
selectively stained th1 cells
breast cancer disease outcome
prognosis classi®cation
regulating macrophage activation
er

000

brca1

metastases

letters
microarray pro®le
gene-expression pro®les
cho mtim-3
health care expenditure
nature
supplementary information accompanies
tumour size greater
grey denotes tumours derived
local lymph nodes
38 er-negative tumours de®ned
95% correct classi®cation
correct classi®cation
cell surface protein
er clustering
prognostic signature
molecular pro®ling
experimental autoimmune encephalomyelitis
nih consensus criteria
adjuvant hormonal therapy
®rst classi®ed
selected 98 primary breast cancers
distant metastases >5 years

correlation
brca1 germline mutation status
100 optimal brca1 reporter genes
th1-dependent autoimmune disease
htim-3
good prognosis group
ells ells ells
19 incorrect classi®cations
cell surface proteins
na rop end
prognostic groups
patient-tailored therapy strategies
invasive breast cancer
recent consensus conferences
classi®ed tumours
good prognosis signature
analysis shows
differentiated th1 cells
urokinase-type plasminogen activator
early breast cancer
breast cancer prognosis
conventional consensus criteria
er-negative cluster
abolishes transcriptional activation
hormonal therapy reduces
gene clustering
upper cluster
epigenetic modi®cation
domain
gene expression patterns
12 good prognosis tumours
er target genes
classi®er
ive ag ritic
human breast cancer
primary breast cancer
breast cancer cells
lymphnode-negative breast cancer
breast cancer
laura
poor prognosis group
optimized sensitivity threshold resulted
er signature prediction
unsupervised
good prognosis category
multifactorial analysis
statistical analysis
multivariate analysis
cyclin d1 expression
determine gene expression
nature
grade 3 lymphocytic infiltrate
authors contributed equally
contrasting patterns discriminate
international consensus panel
harvard medical school
tumour clustering
medical ethical committee
individual sporadic patient
breast cancer tumour
hereditary breast cancer
netherlands cancer institute
dana-farber cancer institute
78 sporadic lymph-node-negative patients
correlation coef®cient
stable puromycin-resistant cells
mass bay area
mammalian cerebral cortex
amersham pharmacia biotech
delayed-type hypersensitivity reactions4
ink-jet oligonucleotide synthesizer
confocal laser scanner
12040 115th avenue ne
distinct effector populations
extracellular helminthic infections
rneasy spin columns
deduced amino-acid sequence
gene expression signature
van der velde
van de vijver*²
control gapdh expression
cells puri®ed
poor prognosis signature
breast cancer res
78 breast cancer patients
breast cancer patients
complete patient data
prognosis reporter genes
breast cancer treatment
®gure shows expression
correlation coef®cients
identify reliably good
5 mg total rna
pairwise similarity metrics
pairwise similarity measures
expression ratio measurements
yellow line consists
poor prognosis patients
natl cancer inst
t7 rna polymerase
sporadic breast cancers
derive complementary rna
nih consensus
th2 cells cross-regulate
human breast tumours
primary breast tumours
classifying breast tumours
39 ihcstained tumours negative
reveals brca1 status
developed distant metastases
receive additional treatment
3 poor prognosis tumours
rene bernards* & stephen
cell-mediated immune responses
pooling equal amounts
prognostic
adjuvant chemotherapy based
identi®es tumours
cho cells transfected
78 sporadic breast tumours
®nal volume 3 ml
discordant brca1 tumour
adjuvant therapy
2/38 misclassi®ed
eosin stained section
murine n-ras gene
expressed sequence tag
receive unnecessary treatment
small primary tumours
classi®cation
brca1 germline mutations
snap-frozen tumour material
yellow line marks
cancers involving brca1
high histological grade
expression data matrix
100 optimal reporter genes
genes chromosomes cancer 14
likelihood ratio test
likelihood ratio test 1
patients remained free
total rna isolation
nuclei showed staining
adverse side effects
sequentially adding subsets
mouse lines commonly
tc2 cells
th1 t-cell clones
netherlands ³ rosetta inpharmatics
discriminating candidate genes
000 human genes synthesized
d10g4 th2

5b6
er negative
developing distant metastases
classi®ed
brca1 mutant tumours
cross validation procedure
estrogen receptor status
signi®cantly regulated
signi®cantly reduces
limited predictive power
usa ³ millennium pharmaceuticals
signi®cantly upregulated
cluster
additional independent set
28-fold odds ratio
®ve discordant cases
tim-3 rna relative
er expression
total rna treated
signal transduction
19 independent sporadic tumours
70 optimal marker genes
dominant expression signatures
remained metastasis free
er status
95% con®dence interval
igv
bottom branch intermingled
optimized sensitivity threshold
`good prognosis
good prognosis
threshold `optimal accuracy
optimal accuracy threshold
twenty-®ve micrograms
th1

ae7

5b6
dominant tumour clusters
predicting disease outcome
average signatures
genes expressed primarily
diagnostic categories based
odds ratio represents
patient group
single 60-polymer
nature
autoimmune diseases
selected speci®cally
autoimmune diseases5
non-redundant mrna sequences
stanford university school
crna labelling
crna
classi®ers
transcriptional activation
diagnostic prediction based
hormonal therapy
authors declare
de®ned
performance cross-validation procedure
selected clinical data
microarray
labelled crnas
sporadic patient
tumour $2 cm
neuro®bromatosis
dashed line patients
cell lines
cell cycle
550 er reporters
clustering
t-helper cells
reference crna pool
breast cancer
550 genes optimally report
brca1 protein
expression patterns
identi®cation
gene expression
axillary metastases
adjuvant treatment
`poor prognosis
5 poor prognosis
poor prognosis
patient data
table s1
sporadic carcinomas
sporadic breast
high grade
er positive
prognosis signature
total rna
powerful tool
nih consensus3
distant metastases
breast cancers
table 1 shows
patients eligible
supplementary information
expression levels
hu25k microarrays represented
single gene
signal
primary tumour
tumour type
received 24 august
50% tumour cells
previous malignancies
tumour cells
expression ratio
relative expression 540 200 2
cell recording
th2 cells
breast tumours
98 breast tumours
cells

100

tim-3

7
human tim-3
misclassi®cation
total 39 er-negative
cancer res
th1 cells
sporadic tumour
disease free
clinical studies
prognosis signatures
brca1 tumour
tumour rna
er-negative group
clinical status
patterns divides
reporter genes
disease outcome
st
gene annotation
similarities measured
surface molecules
brca1 signature
primary tumours
germline mutation
received support
ma

0

activation
upper group
lower group 70%
collaborative group
expression pattern
cancer drugs
sporadic patients
`optimized sensitivity
optimized sensitivity
sporadic cases
optimal accuracy
117 young patients
hereditary patients
distinct roles
oligonucleotide chosen
cy-labelled crna
side effects
potentially suffer
portuguese foundation
transgenic studies
479 biological oligonucleotides
opposite category
brca1 mutation
brca1 mutation 5
98 sporadic tumours
sporadic tumours
distant metastasis
quanti®ed
estrogen receptor
10 t-cell receptor
histopathological data
brca1 tumours
rapid metastases
developing metastases
15 misclassi®cations
281 control probes
crossvalidated predictive
signi®cantly
distinct groups
predictive power
metastasis status
70 marker genes
marker genes
tumour grade 3
odds ratio
cyclin e2
cyclin b2
diagnostic prediction
treatment responses
progressive disease
metastatic disease
hu25k microarray
black negative
vitro transcription
do11
reverse transcription
tumour predisposition
rnase-free h2o
independent factor
show similarity
reported previously7
2 mg ml-1
tumour dendrogram
group consisted
er-positive group
®ve years
including genes
brca1 promoter
brca1 inactivation
rna isolation
th2 cells1±3
developed guidelines
®ve tumours
optimal set
dominant pattern
ernegative signature
er
microarray data
tim-3 enhances
germline carriers
natl acad
actual outcome
predicting outcome
intensity ratio
con®rmed
comparable performance
bottom branch
complete list
clone ae7
functional categories
reference pool14
recent ®ndings
stephen manning³
diagnostic oncology
exact test
individual genes
brca1 signatures
cases based
metastases

letters
van leeuwen
van diest
van waardenburg
activation level
brca2 mutations
cho mock
colour bar
oestrogen receptor
colour scheme
clinical implications
clinical behaviour1±3
clinical parameters
clinical characteristics
brca1 carriers
er-negative tumours
patients receiving
select patients
row represents
®nal concentration
national institutes
similar conclusion
targeted mutation
dashed line
primary diagnosis
validation set
identify optimally
5 years compared
contradictory results
rational development
optimal number
genes expressed
breast-conserving treatment
odds ratios
disease
nature
ernegative tumours
eighteen tumours
38 ernegative tumours
microarray experiments
accuracy improved
microarray agrees
equal amount
brca1
nature
dotted line
approach based
histological grade
versus grade 1
nature
signature
dominant feature
er-positive signature
solid line
rho gtpase
tumour characterized
texas chapters
1 cm
generous donation
signi®cance
30-mm thickness
palo alto
2 cm
randomised trials
ho aw 2
533

© 2002 macmillan magazines
mao mao³
50 mm mes
nih
5% sodium sarcosine
mice heterozygous
neurologic diseases
liquid nitrogen
hongyue dai²³
5 cm
important role
r01 ns38480
molecular carcinogenesis
logistic regression
inkjet technology13
genetic alterations
biomedical genetics
calendar year
ef®cacy
graduated program
metastatic phenotype
silvaa@mednet
immunized lewis
akemi ryu*
adult oncology
twofold difference
greatly reduce
functional annotation
hanspeter waldner*
green®eld*²
10 mm zncl2
aggressive behavior
transcript ratios
monoclonal antibodies
freeman² & vijay
intracellular pathogens
co-stimulatory receptors
tumour-necrosis factor
agioinvasion

log10
ovarian tumors
earlier experiments
histological analyses
green downregulation
dependent variable
correlated alterations
central plains
upper limit
strongest predictors
agilent technologies
formalin-®xed
transgenic mice
promoter hypermethylation
selection criterion
background noise
000 monoclonal antibodies
445

laurent monney*
allergic diseases4
enlarged portion
29 amino acids
lo turco
twodimensional presentation
taqman pcr
short interval
fluorescence intensities
apparently co-regulated
branches displays
tumour types
sjl mice
relevant parameter
© 2002 macmillan magazines
1066 cx amsterdam
tatyana chernova²
promote atopic
531

© 2002 macmillan magazines
640 memorial drive
unselected cohort
ef®ciency
co-regulated genes
000 significant genes
genes belonging
downregulated genes
good
tim-3 cdna
patient
colour plot
high-risk patients
groups studied
therapeutic groups
extensive lymphocytic
disease-free patients
logistic model
applied biology
immunohistochemical staining
monoclonal antibody
multivariate model
scanned images
higher amount
evaluation guidelines
middle panel
microarrays fabricated
predominant induction
regulate induction
preferential induction
metastasis evaluation
nature
evaluating
nature biotechnol
nature genet
nature
guidelines
meeting highlights
chris roberts³
transcript abundance
®nally dissolved
gain insight
naure med
cutting slides
performed independently
accepted 22 november 2001
technical assistance
®ndings provide
/ publications/default
accurate estimate
metastatic risk
rank-ordered list
friend³
* divisions
stephen_friend@merck
nnf foundations
pathological severity
hybridization buffer
angioinvasive growth
potential targets
vivo administration
molecular portraits
prognosis
genes involved
brca2 carriers
larger number
accession number
lower number
calculated based
total
negative
total 18
method includes
details accompany
approximately 50±100 nucleotides
approximately one-
kuchroo*
* center
initial diagnosis
enlargement shown
2 ´ 2 table
remaining samples
dendrograms shown
gene
gender differences
group
left panel
expression
// www
nature med
vitro
acknowledgements
tc1
lines
cells
metastases 2
metastases
poor
control
sporadic
`sporadic
established th1-speci®
disease
correlation
reported
tumour
levels
including
19 young
brca1
th2
developed
derived
matrix
signature
tim-3
outcome
ratio
th1
cancers
predicted
grey
van
data
threshold
clinical
3 patients
7 patients
98 patients
12 patients
78 patients
patients
34 patients
procedure
criteria
distinguish
methods
similar
methods 30
5b6
national
mutation
optimized
prediction
stained
5 years
55 years
development
results
expressed
chemotherapy
7 years
treatment
odds
3 tumours
98 tumours
36 tumours
60

50 tumours

40

30

20

10
tumours
95% accuracy
microarray
er-negative
based
grade 1±3
grade 2±3
selected
staining
mrna
crna
report
method
bottom
speci®
predicting
resulted
interval
signi®
commonly
vegf
rosetta
developing
power
dnase
stanford
pool
snap-frozen
molecular
3c
000 signi®
clusters
histological
greater
university
micrograms
isolation
968 signi®
selection
cross-validation
sequences
subsets
murine
est
category
231 genes
genes
70 genes
100 genes
5 genes
000 genes
solid
metastasis
signatures
groups
usa 98
usa 92
usa 96
usa
usa ²
set
study
identify
brca2
carriers
lymphocytic
represented
applied
immunohistochemical
transcription
model
antibody
scanned
amount
evaluation
treated
3b
panel
microarrays
microarraysð
induction
535

letters
letters
nature
nature
24
nature 382
nature 406
risk
established
med
plot
abundance
provide
feature
highlights
estimate
merck
portraits
left
severity
positive
support
vivo
nnf
/
targets
performed
consisted
rank-ordered
er-positive
dissolved
assistance
er-positive
534
hybridization
november 1±3
labelled
involved
insight
slides
roberts
& friend
molecules
high-risk
growth
display
² number
* number
number
approximately 25
types
approximately 20
approximately 5
black
includes
disease-free
cdna
characterized
center
details
diagnosis 1983±1996
diagnosis
th1-speci®
level
shown
samples
calculated
78 samples
differences
www
circuitry
therapeutics
edward
ref
upa
vector
consistent
& rauvala
+
p-
interferon
slices
refseq
hospital
california 95305
peterse*
er-
assessment
bub1
work
neurons
kerkhoven*
previously8
forty-
manuscript
ncbi
sixteen
² department
series
reached
40 8c
washed
rc
medicine
arizona
pellicer
622del62
rookus
rank
gelber
polychemotherapy
buonomano
similarly
top
percentage
31/44
preparation
matynia
brannan
-
isolated
essential
2c12
edelmann
koks
observation
33/34
®ltrate
orleans
¯ection
fail
lancet 351
lancet 352
unable
//www
extent
improve
heating
contribution
tong
basis
basic
website
25f
co-regulate
il
pathology
reptilian
hans
subgroups
ln0
materials
refs 12
quantitative
â peter
shading
ell
brigham
massachusetts 02115
slade
clustered
augustinus
steps
altered
annab
mucin-
functions
soc
presence
p-values
phrap
panels
eifel
abstract
mid-atlantic
endocrinology 141
il-4
neuroscience
time
n0
angiogenesis
refs 11±14
ron
lls
tamoxifen
4 ´ 10-4
grateful
finally
htm
cost
nlm
favour
tnf
homology
brca124
brca125
change
voikar
behav
umanoff
enriched
apparent
spivak
`leave-one-
pai-1
predict
gabba
sample
divided
outline
thresholds
age #40
physiol
correspondence
schreiber³
ph 6
massachusetts 02139
suggesting
barad
methylation
gordon
george
1a
1c
1b
1d
white
43/78
jacks
berns
transcribed
fct
95% ci 0
95% ci 2
friedman
sorlie
frankland
hematopoietic-speci®
overexpressed
& kriegstein
voskuil
cannon
hedenfalk
95% ci 1
outperform
yield
surgery
64/78
5 yr
reading
530

angiogenesis
schlussel
characterization
overview
period
grants
marc
west
ucla
relatedness
cyclins
fig
parrish
hughes
leaveone-
strain
nederlof
technology
upregulation
develop
html
rodenhuis
median 70%
validate
washington 98034
erkkila
radich
asthma
mcdonald
31 january 2002
& senn
annually
-3 ck
31/34
interleukin
kirkland
1 ´ 10-6
lymphocyte-speci®
2c
notably
mixed
hyperactivation
cambridge
18/44
markedly
yudong
esteller
survived
arranged
sobel§
al
reverse-complementary
valid
35 yr
subdivision
immunoglobulin
sci
caused
bene®
genbank
lou/
decide
fall
32/34
bieche
t2
t1
large
rats
pgk1
eligibility
behaviour
search
kaczmarek
khan
lymphotoxin
corrected
neurosci
science
indicating
compare
suggestions
radiotherapy
formamide
invasion
`leave-oneout
paper
40/44
alter
physiognomy
it4
association
science 287
2a
2b
bilodeau
found
ifn
cdc25b
idea
neurology
raymond
& kucherlapati
vasar
®ltrate15
nacl
differ
12/44
part
signaling
hybridizations
determined
60 8c
majoor
rnazolb
added
reach
sporadic-
approved
exp
34 clustered
ingram
0 ´ 10-8
blanton
tumours26
leave-one-
witteveen*
europe
perou
atopy
brca1-
due
strategy
boston
lakhani
sanders
anthony
determination
ras
engl
rii
grant
diagnosed
purpose
koch
normalized13
121 plesmanlaan
comprise
mcguire
oporto
follow-
il-10
evaluate
manifest
er23
colicelli
cydye
proc
step
gaglia*
chorvatova
fragmented
dalesio
sabatos*
ordered
atsma
contigs
department
kansas
prepared
generated
fisher
age
required
jason
rac2
excluded
continued
95% ci 4±56
macrophages
3a
proliferation
lee
degree
explore
manne
minnesota
marton³
addressed
angioinvasion
goldhirsch
stage
pathol
gendron
linsley³
cooperate
normalized
gov/locuslink/refseq
women
glick
account
effectively
& zhou
her2/neu
regions
gruvberger
collection
72/78
chapman
hartwell
superior
h2
nf1
crucial
them6
date6±12
magnitude
programmed
society
investigate
red
gallen2
8b
allergies9
length
haematoxylin
cy3
cy5
ihc
bms191563
cks2
janicke
org/est_assembly/human/gene_number_methods
steeg
amplitude
discussions
studying
il-13
organ-speci®
30 sections
fact
supported
coyle³
& caldas
candidates
attained
stoughton
abstr
afshari
robustness
correlations
veer*²
p21
terms
erbb4
conclude
respect
addition
treat
gallo-payet
1d6
present
representing 62
surprisingly
encouragement
matthew
hart*
http
anke
c-myc19±22
requests
concordance
chemokine
keratin 18
/1
tcr
brenton
smith
screened
increases
& boyer
martin
zajchowski
aparicio
& verma
pctaire
adrenocorticotropin
overlap
e-mail
®ltration
11b
selecting
analysed
expansion
ci 7±107
carried
column
& payet
rad21
catherine
mad2
function
eae
made
cenpf
hogervorst
illinois
zheng
vol 415
34%
344
345
27%
70±80%
10%
93
92
1995
1994
1997
1996
1999
1998
55%
= 97
873±880
2
342±347
41%
2232±2238
02
01
52
536
150
539±548
90
0
1991
1709±1713
1
82%
658±659
11
10
13
12
15
14
17
16
19
18
²
³
92%
3
83%
23
60
61
65
3±11
= 62
564±569
4
353±361
271±281
91%
673±679
5
= 18
9±6
930±942
-0
194
90%
6
1601±1608
7±11
1451±1467
24
25
26
27
20
21
22
28
29
678±679
77±80
7
9587±9592
97%
10869±10874
~5
72
78
1±19
8
= 35
9212±9217
684±692
0008
203±210
5979±5984
9
67%
= 20
1138±1145
30%
5168±5178
70
227±251
0018
17±28
2000
2001
30
34
= 6
= 4
= 2
= 3
= 0
= 1
0028
94%
5±12
83
705±711
3±94
913±920
57±69
154± 155
15±18
11462±11467
44
979±989
747±752
6

0

­0
1989
70%
